| Oct 24 |
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
|
| Oct 22 |
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
|
| Oct 21 |
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
|
| Oct 18 |
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
|
| Oct 16 |
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra
|
| Oct 9 |
High Growth Tech Stocks To Watch In October 2024
|
| Oct 2 |
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
|
| Oct 1 |
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
|
| Sep 30 |
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
|
| Sep 25 |
Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?
|
